STTR Phase II: Artificial Intelligence (AI)-based Development of Neutralizing Antibodies f — NSF Award to Protabit LLC (CA, $1,000
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) project will lead to the development of engineered neutralizing antibodies for the SARS-CoV-2 virus that can be used as therapeutic agents to diminish the severity of a COVID-19 infection and decrease the chances of hospitalizatio
| Award title | STTR Phase II: Artificial Intelligence (AI)-based Development of Neutralizing Antibodies f |
|---|---|
| Award ID | 2136860 |
| Awardee | Protabit LLC |
| City | PASADENA |
| State | CA |
| Amount obligated | $1,000,000 |
| Principal investigator | Barry Olafson |
| Program | STTR Phase II |
| Start date | 07/01/2022 |
| Abstract | The broader impact/commercial potential of this Small Business Innovation Research (SBIR) project will lead to the development of engineered neutralizing antibodies for the SARS-CoV-2 virus that can be used as therapeutic agents to diminish the severity of a COVID-19 infection and decrease the chances of hospitalization and progressive disease. As the SARS-CoV-2 virus continues to mutate it is necessary to increase collective preparedness by generating a wide collection of neutralizing antibodie |
| Source | NSF Awards |
$799/mo
Try NSFGrants →